CYP2C19 Genotyping Clopidogren (clopidogrel) Blood

CYP2C19 Genotyping – Clopidogrel (Clopidogren), Blood

Test Name: CYP2C19 Genotyping – Clopidogrel
Sample Type: Blood
Method: Molecular genetic testing / PCR-based genotyping

What is the test?

CYP2C19 genotyping identifies genetic variations in the CYP2C19 gene, which affects how the body converts clopidogrel into its active form. The test helps determine whether a patient is likely to have a normal, reduced, or poor response to clopidogrel.

Why is it done?

• To assess genetic response to clopidogrel therapy
• Particularly useful after coronary stenting or acute coronary syndrome
• Helps identify patients who may have reduced clopidogrel activation
• May assist doctors in selecting an appropriate antiplatelet treatment

What does it detect?

Common CYP2C19 variants such as:

• Normal/rapid metabolizer-associated alleles
• Intermediate metabolizer-associated variants
• Poor metabolizer-associated variants, commonly *2 and *3
• Results may be reported using CYP2C19 star-allele/genotype and predicted metabolizer phenotype

Sample Required

Whole blood, collected in an appropriate anticoagulant tube as specified by the laboratory.

Patient Preparation

No special preparation is generally required.

Interpretation

The result should be interpreted by the treating physician along with the patient's clinical condition and other medications. Reduced CYP2C19 activity may result in less conversion of clopidogrel to its active metabolite, potentially reducing its antiplatelet effect.

Important: This genetic test should not be used to start, stop, or change clopidogrel therapy without medical advice.